Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer

[1] Ferlay J(2018)Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 103 356-387

[2] Colombet M(2010)Prevalence, risk factors and clinical implications of malnutrition in french comprehensive cancer centres Br J Cancer 102 966-971

[3] Soerjomataram I(2017)Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer Ann Surg 266 822-830

[4] Pressoir M(2020)Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma Oral Oncol 101 171-177

[5] Desné S(2020)Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap Oral Oncol 19 1285-1292

[6] Berchery D(2001)Body surface area as a determinant of pharmacokinetics and drug dosing Invest New Drugs 29 26-33

[7] Elliott JA(2013)Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation Oncol Rep 71 607-616

[8] Doyle SL(2017)Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer Oral Oncol 5 85-91

[9] Murphy CF(2016)Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens Cancer Med 90 803-813

[10] Chargi N(2015)Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer Lung Cancer 10 947-956

[1] Ferlay J(2018)Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 103 356-387

[2] Colombet M(2010)Prevalence, risk factors and clinical implications of malnutrition in french comprehensive cancer centres Br J Cancer 102 966-971

[3] Soerjomataram I(2017)Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer Ann Surg 266 822-830

[4] Pressoir M(2020)Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma Oral Oncol 101 171-177

[5] Desné S(2020)Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap Oral Oncol 19 1285-1292

[6] Berchery D(2001)Body surface area as a determinant of pharmacokinetics and drug dosing Invest New Drugs 29 26-33

[7] Elliott JA(2013)Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation Oncol Rep 71 607-616

[8] Doyle SL(2017)Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer Oral Oncol 5 85-91

[9] Murphy CF(2016)Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens Cancer Med 90 803-813

[10] Chargi N(2015)Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer Lung Cancer 10 947-956